Is statin use associated with new joint-related symptoms, physical function, and quality of life? Results from two population-based cohorts of women

Arthritis Care and Research

Volumn 67, Issue 1, 2015, Pages 13-20

  Peeters, Geeske ^a   Tett, Susan E ^a   Conaghan, Philip G ^b   Mishra, Gita D ^a   Dobson, Annette J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTHRALGIA; ARTICLE; AUSTRALIA; AUSTRALIAN; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG USE; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; JOINT FUNCTION; JOINT STIFFNESS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COHORT ANALYSIS; HEALTH SURVEY; PROCEDURES; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARTHRALGIA; AUSTRALIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONGITUDINAL STUDIES; MIDDLE AGED; POPULATION SURVEILLANCE; QUALITY OF LIFE;

EID: 84920026366     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22389     Document Type: Article

References (27)

1. Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res 2013;56:348-57.
2. Paraskevas KI. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 2008;27:281-7.
3. Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Baldari CT, et al. Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum 2011;40:430-46.
4. Akasaki Y, Matsuda S, Nakayama K, Fukagawa S, Miura H, Iwamoto Y. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 2009;17:235-43.
5. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis 2005;64:1539-41.
6. Ghosh P, Cheras PA. Vascular mechanisms in osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:693-709.
7. Wu YS, Hu YY, Yang RF, Wang Z, Wei YY. The matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit. Med Hypotheses 2007; 69:557-9.
8. Clockaerts S, van Osch GJ, Bastiaansen-Jenniskens YM, Verhaar JA, van Glabbeek F, van Meurs JB, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012; 71:642-7.
9. Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A, et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010;7:e1000336.
10. Kadam UT, Blagojevic M, Belcher J. Statin use and clinical osteoarthritis in the general population: a longitudinal study. J Gen Intern Med 2013;28:943-9.
11. Beattie MS, Lane NE, Hung YY, Nevitt MC. Association of statin use and development and progression of hip osteoarthritis in elderly women. J Rheumatol 2005;32:106-10.
12. Riddle DL, Moxley G, Dumenci L. Associations between statin use and changes in pain, function and structural progression: a longitudinal study of persons with knee osteoarthritis. Ann Rheum Dis 2013;72:196-203.
13. Dieppe PA. Relationship between symptoms and structural change in osteoarthritis: what are the important targets for therapy? J Rheumatol 2005;32:1147-9.
14. Conaghan PG. The effects of statins on osteoarthritis structural progression: another glimpse of the Holy Grail? Ann Rheum Dis 2012;71:633-4.
15. Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010; 69:483-9.
16. Lee C, Dobson AJ, Brown WJ, Bryson L, Byles J, Warner-Smith P, et al. Cohort profile: the Australian Longitudinal Study on Women's Health. Int J Epidemiol 2005;34:987-91.
17. Australian Department of Health. Pharmaceutical benefits scheme. URL: http://www.pbs.gov.au/pbs/home.
18. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2014. URL: http://www.whocc.no/atc-ddd-index/.
19. McCallum J. The SF-36 in an Australian sample: validating a new, generic health status measure. Aust J Public Health 1995;19:160-6.
20. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
21. Rose MS, Koshman ML, Spreng S, Sheldon R. Statistical issues encountered in the comparison of health-related quality of life in diseased patients to published general population norms: problems and solutions. J Clin Epidemiol 1999;52: 405-12.
22. Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging 2013;8:47-59.
23. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18:401-8.
24. Huddy K, Dhesi P, Thompson PD. Do the frequencies of adverse events increase, decrease, or stay the same with longterm use of statins? Curr Atheroscler Rep 2013;15:301.
25. Australian Department of Health. Expenditure and prescriptions: twelve months to 30 June 2013. URL: http://www.pbs.gov.au/statistics/2012-2013-files/expenditure-and-prescriptions-12-months-to-30-06-2013.pdf.
26. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
27. Brown WJ, Bryson L, Byles JE, Dobson AJ, Lee C, Mishra G, et al. Women's Health Australia: recruitment for a national longitudinal cohort study. Women Health 1998;28:23-40.